PACBPACBHealthcare · Medical Devices

PACB Stock Forecast: Pacific Biosciences of California, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.63
−7.39% on the day

The 8 Wall Street analysts covering Pacific Biosciences of California, Inc. hold a median 12-month price target of $3 — +84.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 68 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$549.5M
Ticker Nerd rank
68/ 100
Median analyst target
$3.00
Analysts covering
8
Revenue$39.0M−1.9% y/y
Operating income−$44.6M
Net income−$44.7M
Free cash flow−$39.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.8%
1M
−16.8%
YTD
−12.8%
1Y
−13.3%
From 52W high
−43.8%
From 52W low
+46.8%
$1.11
$2.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Pacific Biosciences of California, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
68/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Revisions
74
Momentum
62
Quality
54
Value
47
Accruals
45
Volatility
44
Issuance
32

Growth (96): Sales and profits are climbing, and climbing faster than before.

Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PACB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PACB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00Jan 26Apr 26Jul 26Oct 26PACBHigh $3.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
4
Buy
3
Hold
1
Sell
$2.00
Low
$3.00
Median
$3.00
High

The green dot is the last close — the median target sits +84.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
9 Nov 2026UBSMaintainsNeutral$3.05 → $2.70
5 Nov 2026BarclaysMaintainsUnderweight$1.25 → $2.00
5 Nov 2026Piper SandlerReiteratesNeutral$2.00 → $3.00
9 Sept 2026UBSAssumesNeutral$1.50 → $1.35
11 May 2026BarclaysMaintainsUnderweight$1.00 → $1.50
14 Apr 2026BarclaysMaintainsUnderweight—
6 Mar 2026BarclaysDowngradeUnderweight—
15 Dec 2025BarclaysMaintainsEqual-Weight—
11 Nov 2025Piper SandlerMaintainsNeutral—
10 Nov 2025Stephens & Co.MaintainsOverweight—
11 Aug 2025Piper SandlerMaintainsNeutral—
25 June 2025BarclaysMaintainsEqual-Weight—
15 May 2025Piper SandlerMaintainsNeutral—
15 May 2025Stephens & Co.ReiteratesOverweight—
10 Apr 2025Canaccord GenuityMaintainsBuy—
25 Mar 2025ScotiabankMaintainsSector Outperform—
20 Feb 2025Piper SandlerReiteratesNeutral—
18 Feb 2025Goldman SachsMaintainsNeutral—
18 Feb 2025Stephens & Co.ReiteratesOverweight—
14 Feb 2025Stephens & Co.ReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PACB.

Market Radar

This page is one stock. Monday covers all of them.

PACB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PACB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Pacific Biosciences of California, Inc. returned −13.3% against +6.9% for the S&P 500, dividends included.

PACB vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26PACBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PACB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.3×

Cheaper than 33% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
32.4%

Higher than 37% of US stocks

Operating margin
—
Net margin
−81.3%

Higher than 7% of US stocks

Returns & dividend
Return on equity
—
Return on assets
−44.1%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pacific Biosciences of California, Inc. has a market value of $549.5M and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $159.3M. The latest quarter shrank 1.9% year on year.

  • Net income over the same four quarters: −$131.4M, a −82.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.43.

  • Free cash flow in the twelve months to 30 June 2026: −$130.5M.

  • Shares outstanding: 310.8M.

  • Pacific Biosciences of California, Inc. employs 485 people — $328K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

PACB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PACBPacific Biosciences of California, Inc.$549.5M68
AVRAnteris Technologies Global Corp.$485.2M25
RCELAVITA Medical, Inc.$483.1M85
SGHTSight Sciences, Inc.$549.8M85
QDELQuidelOrtho Corp.$567.3M48
TCMDTactile Systems Technology, Inc.$577.4M97
SIShoulder Innovations, Inc.$419.5M63

Take a look at PACB’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Pacific Biosciences of California, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PACB

What is the PACB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Pacific Biosciences of California, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PACB stock a buy right now?

Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pacific Biosciences of California, Inc. 68 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PACB?

As at 21 Nov 2026, Pacific Biosciences of California, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will PACB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +84.0% from the last close, and Ticker Nerd's factor model ranks Pacific Biosciences of California, Inc. 68 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PACB stock forecast for 2030?

No analyst covering Pacific Biosciences of California, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PACB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $3 over the next 12 months.

How has PACB stock performed over the past year?

Pacific Biosciences of California, Inc. returned -13.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pacific Biosciences of California, Inc. do?

Pacific Biosciences of California, Inc. is a life sciences technology company that develops, manufactures, and markets advanced genetic sequencing solutions. Its core offering is HiFi long-read sequencing, supported by Single Molecule, Real-Time technology designed to produce highly accurate, detailed views of DNA.

Company

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. is a life sciences technology company that develops, manufactures, and markets advanced genetic sequencing solutions. Its core offering is HiFi long-read sequencing, supported by Single Molecule, Real-Time technology designed to produce highly accurate, detailed views of DNA. The company provides sequencing instruments, consumables, reagent kits, sample-preparation products, binding kits, and related laboratory solutions for genomic analysis workflows. Its technologies serve research institutions, clinical laboratories, pharmaceutical and biotechnology companies, agricultural organizations, and other customers working with complex genetic material. Applications include human genome and germline analysis, oncology research, infectious disease and microbiology studies, plant and animal sciences, population genomics, and other fields requiring comprehensive DNA characterization. Pacific Biosciences of California, Inc. occupies a specialized role in the genomics market by supporting long-read analysis, which can help researchers investigate genetic regions and structural variations that may be difficult to resolve with shorter sequencing methods.

CEO Mr. Mark Van Oene Ph.D. · 485 employees · United States · https://www.pacb.com